Biocon Ltd, a biopharmaceutical company headquartered in Bengaluru, is set to raise $30 million for its biosimilar unit from a private equity fund managed by Tata Capital Ltd. In a separate development, Canada-based Brookfield Asset Management has initiated talks with Bengaluru-based developer RMZ Corp to acquire a part of its office projects, per a report by VC Circle.
End the Year with a Deal You Can’t Miss!
Subscribe now and save 40% on our premium subscription.
Enjoy unlimited access for a full year at just $199 (usual price $339).
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Offer valid for a limited time – don’t wait to unlock the insights that drive deal-making in Asia!
Subscribe nowAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
